SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ahmed H.)
 

Sökning: WFRF:(Ahmed H.) > Macrophage Activati...

  • Kip, Anke E (författare)

Macrophage Activation Marker Neopterin : A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • 2018-06-01
  • Frontiers Media SA,2018
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-494356
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-494356URI
  • https://doi.org/10.3389/fcimb.2018.00181DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • The Leishmania parasite resides and replicates within host macrophages during visceral leishmaniasis (VL). This study aimed to evaluate neopterin, a marker of macrophage activation, as possible pharmacodynamic biomarker to monitor VL treatment response and to predict long-term clinical relapse of VL. Following informed consent, 497 plasma samples were collected from East-African VL patients receiving a 28-day miltefosine monotherapy (48 patients) or 11-day combination therapy of miltefosine and liposomal amphotericin B (L-AMB, 48 patients). Neopterin was quantified with ELISA. Values are reported as median (inter-quartile range). Baseline neopterin concentrations were elevated in all VL patients at 98.8 (63.9-135) nmol/L compared to reported levels for healthy controls (<10 nmol/L). During the first treatment week, concentrations remained stable in monotherapy patients (p = 0.807), but decreased two-fold compared to baseline in the combination therapy patients (p < 0.01). In the combination therapy arm, neopterin concentrations increased significantly 1 day after L-AMB infusion compared to baseline for cured patients [137 (98.5-197) nmol/L, p < 0.01], but not for relapsing patients [84.4 (68.9-106) nmol/L, p = 0.96]. The neopterin parameter with the highest predictive power for VL relapse was a higher than 8% neopterin concentration increase between end of treatment and day 60 follow-up (ROC AUC 0.84), with a 93% sensitivity and 65% specificity. In conclusion, the identified neopterin parameter could be a potentially useful surrogate endpoint to identify patients in clinical trials at risk of relapse earlier during follow-up, possibly in a panel of biomarkers to increase its specificity.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Wasunna, Monique (författare)
  • Alves, Fabiana (författare)
  • Schellens, Jan H M (författare)
  • Beijnen, Jos H (författare)
  • Musa, Ahmed M (författare)
  • Khalil, Eltahir A G (författare)
  • Dorlo, Thomas P CNetherlands Cancer Institute(Swepub:uu)thodo249 (författare)
  • Netherlands Cancer Institute (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Frontiers in Cellular and Infection Microbiology: Frontiers Media SA8, s. 181-2235-2988

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy